Rankings
▼
Calendar
DNLI (Denali Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena
DNLI
Denali Therapeutics Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$0
Net Income (TTM)
-$513M
EPS (TTM)
-$2.97
Free Cash Flow (TTM)
-$422M
Gross Margin
—
Op. Margin
—
Net Margin
—
FCF Margin
—
P/S Ratio (TTM)
—
P/E Ratio (TTM)
—
YoY Rev Growth
—
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$35M
$35M
-$121M
Q2 23
$294M
$294M
$170M
Q3 23
$1M
$1M
-$114M
Q4 23
$0
$0
-$133M
Q1 24
$0
$0
-$118M
Q2 24
$0
$0
-$117M
Q3 24
$0
$0
-$123M
Q4 24
$0
$0
-$130M
Q1 25
$0
$0
-$146M
Q2 25
$0
$0
-$135M
Q3 25
$0
$0
-$137M
Q4 25
$0
-$3M
-$137M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
33.3x
—
Q2 23
9.9x
—
Q3 23
9.9x
—
Q4 23
10.2x
—
Q1 24
11.4x
—
Q2 24
2667.8x
—
Q3 24
—
—
Q4 24
—
—
Q1 25
—
—
Q2 25
—
—
Q3 25
—
—
Q4 25
—
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$59M
-$62M
Q2 23
-$113M
-$119M
Q3 23
-$87M
-$89M
Q4 23
-$99M
-$101M
Q1 24
-$114M
-$116M
Q2 24
-$91M
-$96M
Q3 24
-$59M
-$63M
Q4 24
-$84M
-$89M
Q1 25
-$131M
-$137M
Q2 25
-$75M
-$80M
Q3 25
-$107M
-$106M
Q4 25
-$99M
-$100M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$3M
Q2 23
$6M
Q3 23
$2M
Q4 23
$2M
Q1 24
$2M
Q2 24
$5M
Q3 24
$4M
Q4 24
$5M
Q1 25
$5M
Q2 25
$4M
Q3 25
$1M
Q4 25
$2M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-16.6%
+43.6%
Q2 23
+460.4%
+8.6%
Q3 23
-64.4%
+3.6%
Q4 23
-100.0%
+14.7%
Q1 24
-100.0%
-24.5%
Q2 24
-100.0%
-5.7%
Q3 24
-100.0%
+7.1%
Q4 24
—
-2.1%
Q1 25
—
+23.7%
Q2 25
—
+15.8%
Q3 25
—
+11.6%
Q4 25
—
+5.8%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$28M
79.9%
Q2 23
$0
0.0%
Q3 23
$27M
2167.3%
Q4 23
$26M
—
Q1 24
$28M
—
Q2 24
$25M
—
Q3 24
$0
—
Q4 24
$25M
—
Q1 25
$25M
—
Q2 25
$0
—
Q3 25
$0
—
Q4 25
$24M
—
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$129M
$27M
—
Q2 23
$98M
$26M
—
Q3 23
$90M
$25M
—
Q4 23
$108M
$25M
—
Q1 24
$107M
$25M
—
Q2 24
$91M
$25M
—
Q3 24
$98M
$25M
—
Q4 24
$100M
$30M
—
Q1 25
$116M
$29M
—
Q2 25
$103M
$32M
—
Q3 25
$102M
$35M
—
Q4 25
$98M
—
$37M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$68M
$1.2B
$1.3B
Q2 23
$132M
$1.1B
$1.2B
Q3 23
$148M
$961M
$1.1B
Q4 23
$127M
$907M
$1.0B
Q1 24
$61M
$876M
$937M
Q2 24
$75M
$821M
$896M
Q3 24
$91M
$746M
$837M
Q4 24
$175M
$657M
$832M
Q1 25
$57M
$761M
$818M
Q2 25
$141M
$758M
$899M
Q3 25
$91M
$757M
$848M
Q4 25
$205M
$663M
$868M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
137M
+2.7%
Q2 23
141M
+3.2%
Q3 23
138M
-2.3%
Q4 23
138M
+0.4%
Q1 24
149M
+8.1%
Q2 24
169M
+13.0%
Q3 24
169M
+0.4%
Q4 24
170M
+0.4%
Q1 25
171M
+0.7%
Q2 25
171M
+0.1%
Q3 25
172M
+0.6%
Q4 25
175M
+1.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 15
—
—
FY 16
—
—
FY 17
$0
130
FY 18
$722K
179
FY 19
$102K
261
FY 20
$1M
291
FY 21
$128K
380
FY 22
$254K
427
FY 23
$743K
445
FY 24
$0
422
FY 25
$0
30K
marketcaparena.com